Is Gossamer Bio Stock a Good Investment?
Gossamer Bio Investment Advice | GOSS |
- Examine Gossamer Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Gossamer Bio's leadership team and their track record. Good management can help Gossamer Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Gossamer Bio's business and its evolving consumer preferences.
- Compare Gossamer Bio's performance and market position to its competitors. Analyze how Gossamer Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Gossamer Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Gossamer Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Gossamer Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Gossamer Bio is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Good | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Gossamer Bio Stock
Researching Gossamer Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 76.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.24. Gossamer Bio had not issued any dividends in recent years.
To determine if Gossamer Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Gossamer Bio's research are outlined below:
| Gossamer Bio is way too risky over 90 days horizon | |
| Gossamer Bio may become a speculative penny stock | |
| Gossamer Bio appears to be risky and price may revert if volatility continues | |
| Gossamer Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 114.7 M. Net Loss for the year was (56.53 M) with profit before overhead, payroll, taxes, and interest of 114.7 M. | |
| Gossamer Bio currently holds about 304.38 M in cash with (3.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Gossamer Bio has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: GOSSAMER BIO Earnings Preview Recent GOSS Insider Trading, Hedge Fund Activity, and More - Nasdaq |
Gossamer Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Gossamer Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Gossamer Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Gossamer Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Gossamer Bio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-03 | 2024-12-31 | -0.168 | -0.15 | 0.018 | 10 | ||
2023-11-09 | 2023-09-30 | -0.26 | -0.21 | 0.05 | 19 | ||
2021-02-25 | 2020-12-31 | -0.79 | -0.88 | -0.09 | 11 | ||
2019-11-12 | 2019-09-30 | -0.69 | -0.8 | -0.11 | 15 | ||
2020-08-11 | 2020-06-30 | -0.86 | -1.0 | -0.14 | 16 | ||
2019-08-08 | 2019-06-30 | -0.56 | -0.74 | -0.18 | 32 | ||
2019-05-14 | 2019-03-31 | -0.65 | -0.9 | -0.25 | 38 | ||
2019-03-22 | 2018-12-31 | -1 | -18.23 | -17.23 | 1723 |
Know Gossamer Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Gossamer Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gossamer Bio backward and forwards among themselves. Gossamer Bio's institutional investor refers to the entity that pools money to purchase Gossamer Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Siren, L.l.c. | 2024-12-31 | 5.2 M | Eversept Partners, Llc | 2024-12-31 | 5 M | Hillhouse Capital Advisors, Ltd. | 2024-12-31 | 5 M | Opaleye Management Inc | 2024-12-31 | 4.5 M | Millennium Management Llc | 2024-12-31 | 3.6 M | Ci Private Wealth Llc | 2024-12-31 | 3.4 M | Rock Springs Capital Management Lp | 2024-12-31 | 3.3 M | Junked Platinum Investment Management Ltd | 2024-12-31 | 3.2 M | Blackrock Inc | 2024-12-31 | 3 M | Octagon Capital Advisors Lp | 2024-12-31 | 18.4 M | Nea Management Company, Llc | 2024-12-31 | 18.1 M |
Gossamer Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 322.65 M.Market Cap |
|
Gossamer Bio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.22) | (0.21) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (1.92) | (1.82) |
Determining Gossamer Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Gossamer Bio is a good buy. For example, gross profit margin measures Gossamer Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Gossamer Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Gossamer Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gossamer Bio. Check Gossamer Bio's Beneish M Score to see the likelihood of Gossamer Bio's management manipulating its earnings.
Evaluate Gossamer Bio's management efficiency
Gossamer Bio has return on total asset (ROA) of (0.1194) % which means that it has lost $0.1194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2254) %, meaning that it created substantial loss on money invested by shareholders. Gossamer Bio's management efficiency ratios could be used to measure how well Gossamer Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.19 in 2025. Return On Capital Employed is likely to gain to -0.21 in 2025. Non Current Assets Total is likely to gain to about 9.2 M in 2025, whereas Total Assets are likely to drop slightly above 299.4 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.13 | 0.12 | |
| Tangible Book Value Per Share | 0.13 | 0.12 | |
| Enterprise Value Over EBITDA | (9.04) | (9.50) | |
| Price Book Value Ratio | 6.94 | 7.29 | |
| Enterprise Value Multiple | (9.04) | (9.50) | |
| Price Fair Value | 6.94 | 7.29 | |
| Enterprise Value | 361.5 M | 589.3 M |
Leadership at Gossamer Bio emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 1.863 |
Basic technical analysis of Gossamer Stock
As of the 21st of March, Gossamer Bio retains the Downside Deviation of 5.23, risk adjusted performance of 0.1751, and Market Risk Adjusted Performance of 0.8753. Gossamer Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Gossamer Bio variance and potential upside to decide if Gossamer Bio is priced fairly, providing market reflects its last-minute price of 1.34 per share. Given that Gossamer Bio is a hitting penny stock territory we urge to closely look at its total risk alpha.Gossamer Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gossamer Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gossamer Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gossamer Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gossamer Bio's Outstanding Corporate Bonds
Gossamer Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Gossamer Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Gossamer bonds can be classified according to their maturity, which is the date when Gossamer Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Gossamer Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Gossamer Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1751 | |||
| Market Risk Adjusted Performance | 0.8753 | |||
| Mean Deviation | 4.7 | |||
| Semi Deviation | 4.5 | |||
| Downside Deviation | 5.23 | |||
| Coefficient Of Variation | 532.57 | |||
| Standard Deviation | 6.24 | |||
| Variance | 38.96 | |||
| Information Ratio | 0.1982 | |||
| Jensen Alpha | 1.26 | |||
| Total Risk Alpha | 1.69 | |||
| Sortino Ratio | 0.2365 | |||
| Treynor Ratio | 0.8653 | |||
| Maximum Drawdown | 36.67 | |||
| Value At Risk | (7.62) | |||
| Potential Upside | 10.38 | |||
| Downside Variance | 27.35 | |||
| Semi Variance | 20.24 | |||
| Expected Short fall | (5.61) | |||
| Skewness | 1.21 | |||
| Kurtosis | 4.03 |
| Risk Adjusted Performance | 0.1751 | |||
| Market Risk Adjusted Performance | 0.8753 | |||
| Mean Deviation | 4.7 | |||
| Semi Deviation | 4.5 | |||
| Downside Deviation | 5.23 | |||
| Coefficient Of Variation | 532.57 | |||
| Standard Deviation | 6.24 | |||
| Variance | 38.96 | |||
| Information Ratio | 0.1982 | |||
| Jensen Alpha | 1.26 | |||
| Total Risk Alpha | 1.69 | |||
| Sortino Ratio | 0.2365 | |||
| Treynor Ratio | 0.8653 | |||
| Maximum Drawdown | 36.67 | |||
| Value At Risk | (7.62) | |||
| Potential Upside | 10.38 | |||
| Downside Variance | 27.35 | |||
| Semi Variance | 20.24 | |||
| Expected Short fall | (5.61) | |||
| Skewness | 1.21 | |||
| Kurtosis | 4.03 |
Consider Gossamer Bio's intraday indicators
Gossamer Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Gossamer Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Gossamer Bio time-series forecasting models is one of many Gossamer Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Gossamer Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Gossamer Stock media impact
Far too much social signal, news, headlines, and media speculation about Gossamer Bio that are available to investors today. That information is available publicly through Gossamer media outlets and privately through word of mouth or via Gossamer internal channels. However, regardless of the origin, that massive amount of Gossamer data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Gossamer Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Gossamer Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Gossamer Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Gossamer Bio alpha.
Gossamer Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Gossamer Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Gossamer Bio Corporate Management
| Colin Rowlings | Senior CMC | Profile | |
| Robert Smith | Chief Officer | Profile | |
| Matt Cravets | Senior Biometrics | Profile | |
| Jeff Boerneke | General Secretary | Profile | |
| Richard MD | Chief Officer | Profile | |
| Mario Orlando | Senior Planning | Profile |
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.